AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
13 Sep 2019
Small Cap Feast
SThree plc (STEM:LON), 432 | Chaarat Gold Holdings Ltd. (CGH:LON), 4.1 | Katoro Gold PLC (KAT:LON), 0.1 | Character Group plc (CCT:LON), 262 | Afentra PLC (AET:LON), 39.4 | Metals Exploration plc (MTL:LON), 4.5 | ANGLE plc (AGL:LON), 12.5 | Asiamet Resources Limited (ARS:LON), 0.6 | Serinus Energy plc (SENX:LON), 2.2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
SThree plc (STEM:LON), 432 | Chaarat Gold Holdings Ltd. (CGH:LON), 4.1 | Katoro Gold PLC (KAT:LON), 0.1 | Character Group plc (CCT:LON), 262 | Afentra PLC (AET:LON), 39.4 | Metals Exploration plc (MTL:LON), 4.5 | ANGLE plc (AGL:LON), 12.5 | Asiamet Resources Limited (ARS:LON), 0.6 | Serinus Energy plc (SENX:LON), 2.2
- Published:
13 Sep 2019 -
Author:
Derren Nathan -
Pages:
2
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019